The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery. These two drugs are commonly used to treat radiation necrosis when it occurs but the hope is that these drugs can be used to prevent radiation necrosis from ever occurring.

The treatment phase of the study is 6 months. Study procedures will be conducted such as: history, physical and neurological exam, pregnancy testing (for women of child bearing age) and a Brain MRI. Follow-up appointments will be every 3 months for 1 year at which time, your participation in the study will be concluded.

Inclusion Criteria:

• Plan to undergo single or five fraction radiosurgery for a metastatic brain tumor
• Diagnosis of a metastatic brain tumor may be accomplished by histologic confirmation or by clinical confirmation by the treating physician based on MR imaging characteristics in the setting of a known history of cancer
• Age > 18 years
• Partial or total resection of a metastatic tumor are eligible

Exclusion Criteria:

• Known sensitivity to vitamin E or Trental
• Recent intracranial bleed or retinal hemorrhage
• Treatment with a non-approved or investigational drug within 30 days before day 1 of study treatment
• History of Avastin treatment
• Anticipated need for treatment with Avastin
• History of bleeding disorder
• History of liver disorder

Adverse Event collection is not specifically mapped out per protocol. The length of the study is 3 years, thus AE collection is up to three years starting from consent.

Adverse events were not systematically collected for all subjects.